Hangzhou Diagens Biotechnology Co., Ltd. (SEHK: 2526)
Health Care · Health Care Equipment & Supplies · CN
HK$370.00
-10.37% today · +76.5% 1Y
Hangzhou Diagens Biotechnology Co., Ltd. (SEHK: 2526) operates in the Health Care Equipment & Supplies industry within the Health Care sector. The company is valued at $4.19B and employs 166 people.
Over the last twelve months the share price has gained 76.5%, trading between 178.00 and 489.00.
Tweenvest scores Hangzhou Diagens Biotechnology Co., Ltd. across four factors: quality 41/100. Its strongest factor is quality.
2526 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.19B
- Revenue (TTM)
- $26.99M
- P/E
- —
- EPS
- -0.84
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$489.00
- 52-week low
- HK$178.00
- Avg volume (3M)
- —
- Shares outstanding
- 88.88M
- Employees
- 166
- Next earnings
- —
About Hangzhou Diagens Biotechnology Co., Ltd.
Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Software and Medical Devices, Technology Licensing, Analysis and Consulting Services, and Others segments. The company's products portfolio include AI AutoVision, a chromosome karyotype assisted diagnosis and analysis system that provides intelligent karyotyping analysis with applications across genetics and hematologic oncology; MetaSight automatic cell microscopic image scanning system, which enables automated scanning, positioning, image acquisition, and output of chromosome or cell samples for a range of cytogenetics applications, including genetics health, radiation health, and hemato-oncology; and KayoFlow automatic cell harvester for pre-analytical processing of various sample types, including peripheral blood, amniotic fluid, and bone marrow. It also offers KayoFlow integrated slide preparation and staining system for pre-analytical slide preparation and staining of chromosome samples; KayoFlow workflow integration systems; and laboratory reagents and consumables. In addition, the company provides integrated storage, computation, training, and inference localized solutions; and iMed MaaS medical imaging AI platform, a cloud-based service platform. Hangzhou Diagens Biotechnology Co., Ltd. was founded in 2016 and is headquartered in Hangzhou, China.
- ISIN
- CNE100007JC7
- Founded
- 2016
- Listed since
- Mar 29, 2026
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Health Care Equipment & Supplies companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Abbott LaboratoriesNYSE: ABT | $200.95B | $116.13 | -0.46% |
| Intuitive Surgical, Inc.NasdaqGS: ISRG | $131.36B | $371.84 | -0.46% |
| Stryker CorporationNYSE: SYK | $126.81B | $330.59 | +0.85% |
| Medtronic plcNYSE: MDT | $116.66B | $91.14 | -1.89% |
| EssilorLuxottica Société anonymeENXTPA: EL | $85.36B | €159.15 | -1.58% |
| Boston Scientific CorporationNYSE: BSX | $72.26B | $49.86 | +1.73% |
| HOYA CorporationTSE: 7741 | $52.49B | ¥24,995.00 | +0.40% |
| Edwards Lifesciences CorporationNYSE: EW | $52.38B | $90.87 | +0.41% |
Figures last refreshed Aug 18, 2026.